Why the study?
The discovery of new peptides and a counter-regulatory pathway has expanded the classical view of the renin-angiotensin system, highlighting its role in obesity and metabolic diseases and providing novel therapeutic targets.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Understanding the counter-regulatory pathways of the renin-angiotensin system provides novel therapeutic targets for managing cardiorenal disorders, obesity, and metabolic diseases.
The classical view of the renin-angiotensin system (RAS) is that of the circulating hormone pathway involved in salt and water homeostasis and blood pressure regulation. It is also involved in the pathogenesis of cardiac and renal disorders. This led to the creation of drugs blocking the actions of this classical pathway, which improved cardiac and renal outcomes. Our understanding of the RAS has significantly expanded with the discovery of new peptides involved in this complex pathway. Over the last two decades, a counter-regulatory or protective pathway has been discovered that opposes the effects of the classical pathway. Components of RAS are also implicated in the pathogenesis of obesity and its metabolic diseases. The continued discovery of newer molecules also provides novel therapeutic targets to improve disease outcomes. This article aims to provide an overview of an updated understanding of the RAS, its role in physiological and pathological processes, and potential novel therapeutic options from RAS for managing cardiorenal disorders, obesity, and related metabolic disorders.
No takes yet. Share an insight, caveat, or question.
Kanugula et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: